{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:29:23Z","timestamp":1794047363491,"version":"4.8.0"},"reference-count":31,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"7","license":[{"start":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T00:00:00Z","timestamp":1593648000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/legalcode"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Fatigue is a common side effect of tyrosine kinase inhibitor (TKI) therapy in chronic myeloid leukemia (CML) patients. However, the prevalence of TKI-induced fatigue remains uncertain and little is known about predictors of fatigue and its relationship with physical activity. In this study, 220 CML patients receiving TKI therapy and 110 gender- and age-matched controls completed an online questionnaire to assess fatigue severity and fatigue predictors (Part 1). In addition, physical activity levels were objectively assessed for 7 consecutive days in 138 severely fatigued and non-fatigued CML patients using an activity monitor (Part 2). We demonstrated that the prevalence of severe fatigue was 55.5% in CML patients and 10.9% in controls (P&lt;0.001). We identified five predictors of fatigue in our CML population: age (OR 0.96, 95% CI 0.93-0.99), female gender (OR 1.76, 95% CI 0.92-3.34), Charlson Comorbidity Index (OR 1.91, 95% CI 1.16-3.13), the use of comedication known to cause fatigue (OR 3.43, 95% CI 1.58-7.44), and physical inactivity (OR of moderately active, vigorously active and very vigorously active compared to inactivity 0.43 (95% CI 0.12-1.52), 0.22 (95% CI 0.06-0.74), and 0.08 (95% CI 0.02-0.26), respectively). Objective monitoring of activity patterns confirmed that fatigued CML patients performed less physical activity on both light (P=0.017) and moderate to vigorous intensity (P=0.009). In fact, compared to the non-fatigued patients, fatigued CML patients performed 1 hour less of physical activity per day and took 2000 fewer steps per day. Our findings facilitate the identification of patients at risk of severe fatigue and highlight the importance to set the reduction of fatigue as a treatment goal in CML care. This study was registered at The Netherlands Trial Registry, NTR7308 (Part 1) and NTR7309 (Part 2).<\/jats:p>","DOI":"10.3324\/haematol.2020.247767","type":"journal-article","created":{"date-parts":[[2020,7,2]],"date-time":"2020-07-02T16:22:27Z","timestamp":1593706947000},"page":"1876-1882","source":"Crossref","is-referenced-by-count":17,"title":["Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity"],"prefix":"10.3324","volume":"106","author":[{"family":"Lando Janssen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Nicole M.A. Blijlevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Meggie M.C.M. Drissen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Esm\u00e9e A. Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Malou A.H. Nuijten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Jeroen J.W.M. Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Silvie Timmers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Maria T.E. Hopman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2020,7,2]]},"reference":[{"key":"27124","doi-asserted-by":"crossref","unstructured":"Bower H, Bjorkholm M, Dickman PW, Hoglund M, Lambert PC, Andersson TM. Life expectancy of patients with chronic myeloid leukemia approaches the life expectancy of the general population. J Clin Oncol. 2016; 34(24):2851-2857.","DOI":"10.1200\/JCO.2015.66.2866"},{"key":"27125","doi-asserted-by":"crossref","unstructured":"Efficace F, Baccarani M, Breccia M. Health-related quality of life in chronic myeloid leukemia patients receiving longterm therapy with imatinib compared with the general population. Blood. 2011; 118(17):4554-4460.","DOI":"10.1182\/blood-2011-04-347575"},{"key":"27126","doi-asserted-by":"crossref","unstructured":"Eliasson L, Clifford S, Barber N, Marin D. Exploring chronic myeloid leukemia patients' reasons for not adhering to the oral anticancer drug imatinib as prescribed. Leuk Res. 2011; 35(5):626-630.","DOI":"10.1016\/j.leukres.2010.10.017"},{"key":"27127","doi-asserted-by":"crossref","unstructured":"Marin D, Bazeos A, Mahon FX. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14):2381-2388.","DOI":"10.1200\/JCO.2009.26.3087"},{"key":"27128","doi-asserted-by":"crossref","unstructured":"Efficace F, Baccarani M, Breccia M. Chronic fatigue is the most important factor limiting health-related quality of life of chronic myeloid leukemia patients treated with imatinib. Leukemia. 2013; 27(7):1511-1519.","DOI":"10.1038\/leu.2013.51"},{"key":"27129","doi-asserted-by":"crossref","unstructured":"Caldemeyer L, Dugan M, Edwards J, Akard L. Long-term side effects of tyrosine kinase inhibitors in chronic myeloid leukemia. Curr Hematol Malign Rep. 2016; 11(2):71-79.","DOI":"10.1007\/s11899-016-0309-2"},{"key":"27130","doi-asserted-by":"crossref","unstructured":"Winters-Stone KM, Bennett JA, Nail L, Schwartz A. Strength, physical activity, and age predict fatigue in older breast cancer survivors. Oncol Nurs Forum. 2008; 35(5):815-821.","DOI":"10.1188\/08.ONF.815-821"},{"key":"27131","doi-asserted-by":"crossref","unstructured":"Engberg I, Segerstedt J, Waller G, Wennberg P, Eliasson M. Fatigue in the general population- associations to age, sex, socioeconomic status, physical activity, sitting time and selfrated health: the northern Sweden MONICA study 2014. BMC Public Health. 2017; 17(1):654.","DOI":"10.1186\/s12889-017-4623-y"},{"key":"27132","doi-asserted-by":"crossref","unstructured":"Bower JE. Cancer-related fatigue--mechanisms, risk factors, and treatments. Nat Rev Clin Oncol. 2014; 11(10):597-609.","DOI":"10.1038\/nrclinonc.2014.127"},{"key":"27133","doi-asserted-by":"crossref","unstructured":"Oberoi S, Robinson PD, Cataudella D. Physical activity reduces fatigue in patients with cancer and hematopoietic stem cell transplant recipients: a systematic review and meta-analysis of randomized trials. Crit Rev Oncol Hematol. 2018; 122:52-59.","DOI":"10.1016\/j.critrevonc.2017.12.011"},{"key":"27134","unstructured":"Braspenning KAE HR, Nowee M, Janssen J, Westerweel PE, Blijlevens NMA. CMyLife: een eerste inzicht in kwaliteit van leven en verbetermogelijkheden bij CML-pati\u00ebnten voorafgaand aan gebruik van CMyLife. Nederlands Tijdschrift voor Hematologie. 2017; 4:183-189."},{"key":"27135","doi-asserted-by":"crossref","unstructured":"Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G. Dimensional assessment of chronic fatigue syndrome. J Psychosom Res. 1994; 38(5):383-392.","DOI":"10.1016\/0022-3999(94)90099-X"},{"key":"27136","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"27137","doi-asserted-by":"crossref","unstructured":"Ryan CG, Grant PM, Tigbe WW, Granat MH. The validity and reliability of a novel activity monitor as a measure of walking. Br J Sports Med. 2006; 40(9):779-784.","DOI":"10.1136\/bjsm.2006.027276"},{"key":"27138","doi-asserted-by":"crossref","unstructured":"Egerton T, Chastin SF, Stensvold D, Helbostad JL. Fatigue may contribute to reduced physical activity among older people: an observational study. J Gerontol A Biol Sci Med Sci. 2016; 71(5):670-676.","DOI":"10.1093\/gerona\/glv150"},{"key":"27139","doi-asserted-by":"crossref","unstructured":"O'Brien SG, Guilhot F, Larson RA. Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic- phase chronic myeloid leukemia. N Engl J Med. 2003; 348(11):994-1004.","DOI":"10.1056\/NEJMoa022457"},{"key":"27140","doi-asserted-by":"crossref","unstructured":"Kalmanti L, Saussele S, Lauseker M. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia. 2015; 29(5):1123-1132.","DOI":"10.1038\/leu.2015.36"},{"key":"27141","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Shah NP, Hochhaus A. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2260-2270.","DOI":"10.1056\/NEJMoa1002315"},{"key":"27142","doi-asserted-by":"crossref","unstructured":"Saglio G, Kim DW, Issaragrisil S. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-2259.","DOI":"10.1056\/NEJMoa0912614"},{"key":"27143","doi-asserted-by":"crossref","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger MW. Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial. J Clin Oncol. 2018; 36(3):231-237.","DOI":"10.1200\/JCO.2017.74.7162"},{"key":"27144","doi-asserted-by":"crossref","unstructured":"Lipton JH, Chuah C, Guerci-Bresler A. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2016; 17(5):612-621.","DOI":"10.1016\/S1470-2045(16)00080-2"},{"key":"27145","doi-asserted-by":"crossref","unstructured":"Zordan R, Manitta V, Nandurkar H, Cole- Sinclair M, Philip J. Prevalence and predictors of fatigue in haemo-oncological patients. Intern Med J. 2014; 44(10):1013-1017.","DOI":"10.1111\/imj.12517"},{"key":"27146","doi-asserted-by":"crossref","unstructured":"Ruffer JU, Flechtner H, Tralls P. Fatigue in long-term survivors of Hodgkin's lymphoma; a report from the German Hodgkin Lymphoma Study Group (GHSG). Eur J Cancer. 2003; 39(15):2179-2186.","DOI":"10.1016\/S0959-8049(03)00545-8"},{"key":"27147","doi-asserted-by":"crossref","unstructured":"Butt Z, Rao AV, Lai JS, Abernethy AP, Rosenbloom SK, Cella D. Age-associated differences in fatigue among patients with cancer. J Pain Symptom Manage. 2010; 40(2):217-223.","DOI":"10.1016\/j.jpainsymman.2009.12.016"},{"key":"27148","doi-asserted-by":"crossref","unstructured":"Tibubos AN, Ernst M, Brahler E. Fatigue in survivors of malignant melanoma and its determinants: a register-based cohort study. Support Care Cancer. 2019; 27(8):2809-2818.","DOI":"10.1007\/s00520-018-4587-1"},{"key":"27149","doi-asserted-by":"crossref","unstructured":"Nacul LC, Lacerda EM, Pheby D. Prevalence of myalgic encephalomyelitis\/ chronic fatigue syndrome (ME\/CFS) in three regions of England: a repeated cross-sectional study in primary care. BMC Med. 2011; 9:91.","DOI":"10.1186\/1741-7015-9-91"},{"key":"27150","doi-asserted-by":"crossref","unstructured":"Jason LA, Richman JA, Rademaker AW. A community-based study of chronic fatigue syndrome. Arch Intern Med. 1999; 159(18):2129-2137.","DOI":"10.1001\/archinte.159.18.2129"},{"key":"27151","doi-asserted-by":"crossref","unstructured":"Bensing JM, Hulsman RL, Schreurs KM. Gender differences in fatigue: biopsychosocial factors relating to fatigue in men and women. Med Care. 1999; 37(10):1078-1083.","DOI":"10.1097\/00005650-199910000-00011"},{"key":"27152","doi-asserted-by":"crossref","unstructured":"Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev. 2012; 11:CD006145.","DOI":"10.1002\/14651858.CD006145.pub3"},{"key":"27153","doi-asserted-by":"crossref","unstructured":"Piercy KL, Troiano RP, Ballard RM. The physical activity guidelines for Americans. JAMA. 2018; 320(19):2020-2028.","DOI":"10.1001\/jama.2018.14854"},{"key":"27154","doi-asserted-by":"crossref","unstructured":"Rogers MP, Orav J, Black PM. The use of a simple Likert scale to measure quality of life in brain tumor patients. J Neurooncol. 2001; 55(2):121-131.","DOI":"10.1023\/A:1013381816137"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/9797\/71012","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9797\/71013","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/9797\/71012","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T09:57:32Z","timestamp":1794045452000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/9797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,2]]},"references-count":31,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2020.247767","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2020,7,2]]}}}